These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25801051)

  • 1. Re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. Eur Urol 2015;67:212-9.
    Bogdanović J; Sekulić V
    Eur Urol; 2015 Aug; 68(2):e35-6. PubMed ID: 25801051
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. Eur Urol 2015;67:212-9: Extended Lymph Node Dissection and the Will Rogers Phenomenon.
    Froehner M; Wirth MP
    Eur Urol; 2015 Jun; 67(6):e112. PubMed ID: 25282364
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Jovo Bogdanović and Vuk Sekulić's Letter to the Editor re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. Eur Urol 2015;67:212-9.
    Abdollah F; Montorsi F; Briganti A
    Eur Urol; 2015 Aug; 68(2):e37-8. PubMed ID: 25801052
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Giorgio Gandaglia, Elio Mazzone, Armando Stabile, et al. Prostate-specific Membrane Antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study. Eur Urol.2022;82:411-18.
    Wang B; Li C; Zheng X; Yao K; Wang L
    Eur Urol; 2023 Jan; 83(1):e31-e32. PubMed ID: 36210216
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Chris Parker, Matthew R. Sydes and Howard Kynaston's letter to the editor re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
    Abdollah F; Briganti A
    Eur Urol; 2013 Nov; 64(5):e103-4. PubMed ID: 23915876
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Sanoj Punnen, Matthew R. Cooperberg, Anthony V. D'Amico, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.025: Re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
    Parker C; Sydes MR; Kynaston H;
    Eur Urol; 2013 Nov; 64(5):e102. PubMed ID: 23953599
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Carlo A. Bravi, Nicoal Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Eur Urol 2020;78:661-9.
    Achard V; Dal Pra A; Zilli T
    Eur Urol; 2020 Dec; 78(6):e221-e222. PubMed ID: 33008661
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Francesco Montorsi and Giorgio Gandaglia's letter to the editor re: Georgios Gakis, Stephen A. Boorjian, Alberto Briganti, et al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur urol 2014;66:191-9.
    Gakis G; Stief CG
    Eur Urol; 2014 Dec; 66(6):e109-10. PubMed ID: 25204223
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Vérane Achard, Alan Dal Pra, and Thomas Zilli's Letter to the Editor re: Carlo A. Bravi, Nicola Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Eur Urol 2020;78:661-9.
    Bravi CA; Montorsi F; Briganti A
    Eur Urol; 2020 Dec; 78(6):e223-e224. PubMed ID: 33023772
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Alberto Briganti, Giorgio Gandaglia, Markus Graefen, Steven Joniau, R. Jeffrey Karnes, and Francesco Montorsi's Letter to the Editor re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol 2021;79:595-604. Time for a Change? Clinically Meaningful Reasons Why We Will Continue Performing Extended Pelvic Lymph Node Dissection in Selected Patients with Prostate Cancer.
    Lestingi JFP; Trinh QD; Coelho RF; Pontes J; Bastos DA; Nahas WC
    Eur Urol; 2021 Jun; 79(6):e184-e185. PubMed ID: 33685836
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Alberto Briganti, Umberto Capitanio, Felix K.-H. Chun, et al. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol 2008;54:794-804.
    Cai T; Nesi G; Bartoletti R
    Eur Urol; 2009 Feb; 55(2):e32-3; author reply e34-5. PubMed ID: 18760527
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Georgios Gakis, Stephen A. Boorjian, Alberto Briganti, et al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur urol 2014;66:191-9.
    Montorsi F; Gandaglia G
    Eur Urol; 2014 Dec; 66(6):e107-8. PubMed ID: 25204224
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Alberto Briganti, Umberto Capitanio, Felix K.-H. Chun, et al. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol 2008;54:794-804.
    Bogdanovic J; Sekulic V
    Eur Urol; 2008 Oct; 54(4):955-6. PubMed ID: 18687518
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Alberto Briganti, Michael L. Blute, James H. Eastham, et al. Pelvic lymph node dissection in prostate cancer. Eur urol 2009;55:1251-65.
    Alcover J; Filella X
    Eur Urol; 2009 Dec; 56(6):e53. PubMed ID: 19773114
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Firas Abdollah, Maxine Sun, Rodolphe Thuret, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011;59:88-95.
    Simone CB; Simone CB
    Eur Urol; 2011 May; 59(5):e29-30; author reply e31-2. PubMed ID: 21296483
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Francesco Montorsi, Nicola Fossati, Carlo A. Bravi, Giorgio Gandaglia, Nazareno Suardi, and Alberto Briganti's Letter to the Editor re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. Eur Urol 2021;79:537-44. Surgical Treatment of Local Recurrence Following Radical Prostatectomy: Reality or Illusion?
    Knipper S; Maurer T
    Eur Urol; 2021 May; 79(5):e134. PubMed ID: 33579574
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Jesse D. Sammon, Firas Abdollah, Anthony D'Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol 2015;68:756-65.
    Sammon JD; Abdollah FA; Trinh QD
    Eur Urol; 2016 Jun; 69(6):e129. PubMed ID: 26461111
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Armando Stabile, Antony Pellegrino, Elio Mazzone, et al. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Eur Urol Oncol 2022;5:1-17.
    Chen K; O'Brien J; McVey A; Kasivisvanathan V; Murphy DG
    Eur Urol Oncol; 2022 Jun; 5(3):375-376. PubMed ID: 35331682
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Firas Abdollah, Maxine Sun, Jan Schmitges, et al. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol 2011;60:920-30.
    Froehner M
    Eur Urol; 2012 Feb; 61(2):e11; author reply e12. PubMed ID: 22093294
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Alberto Martini, Giorgio Gandaglia, R. Jeffrey Karnes, et al. Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. Eur Urol Oncol 2019;2:456-63.
    Giannarini G; Crestani A; Ficarra V
    Eur Urol Oncol; 2019 Jul; 2(4):472-473. PubMed ID: 31277786
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.